These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34199384)

  • 21. Ca
    Straus MR; Tang T; Lai AL; Flegel A; Bidon M; Freed JH; Daniel S; Whittaker GR
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospects for a MERS-CoV spike vaccine.
    Zhou Y; Jiang S; Du L
    Expert Rev Vaccines; 2018 Aug; 17(8):677-686. PubMed ID: 30058403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
    Tang J; Zhang N; Tao X; Zhao G; Guo Y; Tseng CT; Jiang S; Du L; Zhou Y
    Hum Vaccin Immunother; 2015; 11(5):1244-50. PubMed ID: 25874632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccines for the prevention against the threat of MERS-CoV.
    Du L; Tai W; Zhou Y; Jiang S
    Expert Rev Vaccines; 2016 Sep; 15(9):1123-34. PubMed ID: 26985862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor-binding domain-based subunit vaccines against MERS-CoV.
    Zhang N; Tang J; Lu L; Jiang S; Du L
    Virus Res; 2015 Apr; 202():151-9. PubMed ID: 25445336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
    Jiang S; Hillyer C; Du L
    Trends Immunol; 2020 May; 41(5):355-359. PubMed ID: 32249063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.
    Xiang R; Wang Y; Wang L; Deng X; Huo S; Jiang S; Yu F
    Curr Opin Virol; 2022 Apr; 53():101199. PubMed ID: 35038651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys.
    Saunders KO; Lee E; Parks R; Martinez DR; Li D; Chen H; Edwards RJ; Gobeil S; Barr M; Mansouri K; Alam SM; Sutherland LL; Cai F; Sanzone AM; Berry M; Manne K; Kapingidza AB; Azoitei M; Tse LV; Scobey TD; Spreng RL; Rountree RW; DeMarco CT; Denny TN; Woods CW; Petzold EW; Oguin TH; Sempowski GD; Gagne M; Douek DC; Tomai MA; Fox CB; Seder R; Wiehe K; Weissman D; Pardi N; Acharya P; Andersen H; Lewis MG; Moore IN; Montefiori DC; Baric RS; Haynes BF
    bioRxiv; 2021 Feb; ():. PubMed ID: 33619494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein.
    Chen Y; Lu S; Jia H; Deng Y; Zhou J; Huang B; Yu Y; Lan J; Wang W; Lou Y; Qin K; Tan W
    Emerg Microbes Infect; 2017 May; 6(5):e37. PubMed ID: 28536429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Searching for animal models and potential target species for emerging pathogens: Experience gained from Middle East respiratory syndrome (MERS) coronavirus.
    Vergara-Alert J; Vidal E; Bensaid A; Segalés J
    One Health; 2017 Jun; 3():34-40. PubMed ID: 28616501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patents Related to Pathogenic Human Coronaviruses.
    Dos Santos M; Ferreira AVF; da Silva JO; Nogueira LM; Machado JM; Francisco MFC; da Paz MC; Giunchetti RC; Galdino AS
    Recent Pat Biotechnol; 2021; 15(1):12-24. PubMed ID: 33504319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization against Medically Important Human Coronaviruses of Public Health Concern.
    Nimer NA; Nimer SN
    Can J Infect Dis Med Microbiol; 2024; 2024():9952803. PubMed ID: 38938549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19.
    Lee P; Kim DJ
    Immune Netw; 2020 Aug; 20(4):e28. PubMed ID: 32895615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses.
    Venkataraman S
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccines against Coronaviruses: The State of the Art.
    Conte C; Sogni F; Affanni P; Veronesi L; Argentiero A; Esposito S
    Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32560340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologically active compounds from marine organisms in the strategies for combating coronaviruses.
    Zaporozhets TS; Besednova NN
    AIMS Microbiol; 2020; 6(4):470-494. PubMed ID: 33364539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.
    Padron-Regalado E
    Infect Dis Ther; 2020 Jun; 9(2):255-274. PubMed ID: 32328406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use.
    Vasireddy D; Atluri P; Malayala SV; Vanaparthy R; Mohan G
    J Clin Med Res; 2021 Apr; 13(4):204-213. PubMed ID: 34007358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.
    Tse LV; Meganck RM; Graham RL; Baric RS
    Front Microbiol; 2020; 11():658. PubMed ID: 32390971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses.
    Oreshkova N; Myeni SK; Mishra N; Albulescu IC; Dalebout TJ; Snijder EJ; Bredenbeek PJ; Dallmeier K; Kikkert M
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.